Head Lice Product Registration in UK

11 December 2012

TyraTech, Inc.

(the "Company" or "TyraTech")

TyraTech Receives Head Lice Product Registration in UK

TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has received notification from the U.K. regulatory body, the Medicines and Healthcare products Regulatory Agency ('MHRA'), that the Company's head lice product VaMOUSSE!™ has been registered with the MHRA as a Class I medical device. As a Class I medical device, VaMOUSSE!™ will be subject to the lowest level of regulatory oversight.

David Paton, TyraTech's Head of European Operations, said, "We are excited to have received our first product registration in the UK. VaMOUSSE!™ is the first in a range of products we envision for the removal, treatment and prevention of head lice infestations. We are actively seeking retail partners to distribute our product under their own store brands or through other channels under our brand VaMOUSSE!™. We expect the product to be launched in the first half of 2013."

 ##

For further information please contact:

TyraTech Inc.Alan Reade, Executive ChairmanTel: +1 919 415 4310

Peter Jerome, Chief Financial OfficerTel: +1 919 415 4280

N+1 Singer, Nominated Adviser and Joint BrokerAubrey Powell / Alex WrightTel: +44 20 7496 3000

First Columbus LLP, Joint BrokerChris CrawfordTel: +44 20 3002 2070